Gannex Pharma Co., Ltd. clinical trials

A subsidiary of Ascletis Pharma Inc.

The registry lists 9 studies whose lead sponsor is Gannex Pharma Co., Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 8, 2025.

Studies

Recruiting first, then most recently updated. Showing 9 of 9. All Ascletis Pharma Inc. studies →

• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 Tablets in Adult Patients With NASHActive, not recruitingNCT05462353Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of ASC42 in Healthy SubjectsCompletedNCT04679129Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety, Tolerability, and Efficacy of ASC41 in Adults With NASHWithdrawnNCT05118360Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese SubjectsCompletedNCT04686994Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Effect of Food on the Pharmacokinetics of ASC41 in Healthy VolunteersCompletedNCT04692025Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• DDI Study of ASC41 in HV and the PK, Safety and Tolerability in Subjects With NAFLD.CompletedNCT04845646Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy SubjectsCompletedNCT05118516Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Study to Evaluate the Safety and Efficacy of ASC42 Tablets in Subjects With Primary Biliary CholangitisCompletedNCT05190523Phase 2

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.

• Drug Interaction Study of ASC42 With AtorvastatinCompletedNCT05464628Phase 1

  Sponsor listed in the registry: Gannex Pharma Co., Ltd.